Firms on GLP-1 import records

Which firms and countries appear in FDA import records for GLP-1 drugs?

FDA’s Import Alert 66-80, published Oct 9, 2026, says FDA divisions “may detain without physical examination (DWPE) shipments of GLP-1 APIs offered for entry, except for the products and firms identified on the Green List.” The Green List has 21 entries: China (12), India (3), Belgium (1), Canada (1), Denmark (1), Ireland (1), Italy (1) and Portugal (1). FDA redacts every Green List firm name, so the list shows countries and drugs, not companies. FDA’s import refusal records list 717 refused shipment lines whose product code names semaglutide, tirzepatide, liraglutide, retatrutide or GLP-1, dated Jun 16, 2023 to Oct 30, 2026; 32 of them carry an API or powder product code listed on the alert, most often from China (27), Hong Kong (2) and Canada (1).

Records read Nov 15, 2026. Import refusal files searched cover Jan 1, 2002 to Oct 30, 2026. A refusal line is one product line on an import entry that FDA refused; the declared manufacturer is the firm the importer named, not necessarily the firm that made the product.

Answer pages: Where does compounded semaglutide API come from? FDA import records by country, What is FDA’s GLP-1 API Green List (Import Alert 66-80)?, How many GLP-1 import shipments has FDA refused, and from which countries?.

Import Alert 66-80 Green List

Import Alert 66-80, “Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances” (DWPE, published Oct 9, 2026). FDA’s heading for the list: “List of firms and their drugs that have met the criteria for exclusion from recommendation for Detention Without Physical Examination (DWPE) under this Import Alert (a.k.a. Green List)” The entries below are in FDA’s order; FDA prints a redaction in place of each firm name.

Product codes and drugs listed
1Redacted by FDABELGIUM61P[][]72 Semaglutide (Anti-Diabetic)
61P[][]75 Exenatide (Anti-Diabetic)
2Redacted by FDACANADA61P[][]74 Tirzepatide (Anti-Diabetic)
3Redacted by FDACHINA56F[][]99 Peptide N.E.C. (Antibiotics), and the importer description contains the word, [redacted]
61P[][]77 Orforglipron (Anti-Diabetic)

61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) and the importer description contains the word, [redacted]

61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) [redacted]
4Redacted by FDACHINA56F[][]99 Peptide N.E.C. (Antibiotics)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic)
5Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
6Redacted by FDACHINA61P[][]74 Tirzepatide (Anti-Diabetic)
7Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
8Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
9Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
10Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
11Redacted by FDACHINA61P[][]74 Tirzepatide (Anti-Diabetic)
61P[][]77 Orforglipron (Anti-Diabetic)
12Redacted by FDACHINA61P[][]72 Semaglutide (Anti-Diabetic)
61P[][]74 Tirzepatide (Anti-Diabetic)
13Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
14Redacted by FDACHINA56F[][]99 Peptide N.E.C. (Antibiotics) [redacted]
61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) [redacted]

64R[][]99 Hormone N.E.C. (Hormone) [redacted]
15Redacted by FDADENMARK61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)
16Redacted by FDAINDIA61P[][]76 Liraglutide (Anti-Diabetic)
17Redacted by FDAINDIA61P[][]75 Exenatide (Anti-Diabetic)
18Redacted by FDAINDIA61P[][]76 Liraglutide (Anti-Diabetic)
19Redacted by FDAIRELAND58H[][]06 Dulaglutide (Endocrine-Metabolic Agent)
61P[][]77 Orforglipron (Anti-Diabetic)
20Redacted by FDAPORTUGAL61P[][]72 Semaglutide (Anti-Diabetic)
61P[][]77 Orforglipron SDD (Anti-Diabetic)
21Redacted by FDAITALY61P[][]76 Liraglutide (Anti-Diabetic)

More on what the list is and the alert’s full reason text: What is FDA’s GLP-1 API Green List?

Refused GLP-1 shipment lines by country

All 717 lines, and the 32 whose product code Import Alert 66-80 lists as an API or powder form.

CountryAll linesAPI or powder code lines
Canada2511
Denmark1490
United States590
China4227
United Kingdom420
India320
Colombia190
Italy130
Mexico130
Japan110
Bangladesh100
Brazil90
France90
Netherlands70
Turkey70
Germany61
Vietnam60
Hong Kong52
Singapore40
Lithuania30
Switzerland31
Israel20
Nigeria20
Philippines20
Albania10
Australia10
Bulgaria10
Egypt10
Greece10
Honduras10
Indonesia10
Paraguay10
Poland10
Portugal10
United States Outlying Islands10

By drug named in the product code

Semaglutide501
Tirzepatide201
Retatrutide11
Liraglutide4

Firms named as manufacturer on refused GLP-1 lines

67 firms have a page, one per spelling and country as FDA wrote it. The declared manufacturer is the name the importer entered on the line.

Fujian Genohope Biotech LtdChina97Tirzepatide, SemaglutideMay 28, 2025
Zhejiang Peptites Biotech Co.,Ltd.China64Tirzepatide, SemaglutideMar 15, 2024
ELIE PHARMACYCanada50SemaglutideMay 13, 2024
Incepta Pharmaceuticals LtdBangladesh50SemaglutideFeb 7, 2026
PharmazonUnited Kingdom50Semaglutide, TirzepatideOct 24, 2025
Qingdao Biopeptek Co., Ltd.China43Semaglutide, TirzepatideJan 25, 2024
SHREE PHARMAIndia40TirzepatideJan 9, 2026
COMEM NATURAL JSCVietnam30RetatrutideSep 24, 2026
N EDGE GROUP INCCanada30RetatrutideAug 25, 2026
XU LIHUA JINGFANG Trading Co. LTDChina32Retatrutide, Tirzepatide, SemaglutideOct 7, 2026
Ziska Pharmaceuticals Ltd.India30Tirzepatide, SemaglutideMay 4, 2026
BRITANNICA REMEDY'S RX PHARMACYCanada20SemaglutideDec 18, 2025
CMB MEDICINA UABLithuania20TirzepatideJun 20, 2025
DAY PHARMA EIRELIBrazil20SemaglutideMay 22, 2024
Hangzhou ThinHeal Pharma-Tech Co., Ltd.China22Semaglutide, TirzepatideMay 1, 2025
Harbin Jixianglong Biotech Co., Ltd.China21Semaglutide, TirzepatideAug 6, 2025
Hybio Pharmaceutical Co., Ltd.China21Semaglutide, TirzepatideJun 30, 2026
PARKWAY PHARMACYCanada20Tirzepatide, SemaglutideJan 3, 2025
ROYALDAY COMPANY LIMITEDHong Kong20SemaglutideJan 28, 2026
SHANGHAI SHUNYI TRADE CO LTDChina21Tirzepatide, RetatrutideOct 7, 2026
ZISKA PHARMABangladesh20TirzepatideMay 5, 2026
ACI PHARMACEUTICALS LTDBangladesh10TirzepatideAug 15, 2024
AndersonBrecon Inc.United States10TirzepatideJun 18, 2026
AP CARGO INTERNATIONAL FREIGHT INC.Philippines10SemaglutideSep 23, 2024
APSIN PHARMACEUTICAL LTDIndia10TirzepatideJun 18, 2025
ASIAN SUITS ONLINE LIMITEDUnited Kingdom10SemaglutideJul 13, 2026
BELJING YIYUAN TECHNOLOGY GROUPChina10TirzepatideDec 10, 2025
BIOAMINO LABSGermany11TirzepatideSep 14, 2026
Cayman Chemical Company, Inc.United States10SemaglutideNov 1, 2024
CELEB CLINICNigeria10SemaglutideMay 31, 2024
CHONGUHAN MEDICAL TECHNOLOGIESChina10TirzepatideJul 24, 2026
DALIAN HANDOM CHEMChina10SemaglutideFeb 13, 2024
DROGUERIA LA REBAJA PLUSColombia10SemaglutideNov 12, 2024
DYNAMIC GROUPCanada11TirzepatideMay 19, 2025
ELIE WELLNESSCanada10SemaglutideSep 26, 2024
FELIX HEALTHCanada10SemaglutideAug 8, 2025
Gene ProteinsSwitzerland11TirzepatideFeb 25, 2026
HONG KONG KAIYS TRADING LIMITEDHong Kong11TirzepatideFeb 3, 2026
Hubei JXBio Pharmaceutical Co., Ltd.China11TirzepatideAug 5, 2024
Hybio Pharmaceutical (Wuhan) Co., Ltd.China11SemaglutideMay 14, 2026
JASONS CANDA DRUGSTORECanada10SemaglutideMay 13, 2024
JB PHARMAIndia10TirzepatideDec 5, 2025
JBL INTERNATIONAL HK LIMITEDHong Kong11TirzepatideApr 30, 2024
Lifecar Neuro Products LtdIndia10TirzepatideMay 28, 2025
Marks Marine PharmacyCanada10SemaglutideFeb 20, 2026
MetaTide HealthcareSwitzerland10RetatrutideOct 2, 2026
NANJING HANXIN INTERNATIONALChina11SemaglutideMay 19, 2026
NOVO PHARMACanada10SemaglutideDec 12, 2025
PASTURE PHARMA PTE LTDSingapore10SemaglutideAug 26, 2025
PB PHARMA GMBHGermany10SemaglutideApr 12, 2024
PEPTIDE SCIENCESIndia10TirzepatideDec 18, 2025
Pharmhub PharmacyUnited Kingdom10SemaglutideJun 12, 2026
SENOVA BIOPHARM CO LTDHong Kong10TirzepatideNov 10, 2025
SHARMA BROTHER'S INTERNATIONALIndia10TirzepatideJun 21, 2024
SHENZHEN JYMED TECHNOLOGY CO., LTD.China11TirzepatideNov 27, 2023
SIMPLIPHARM PHARMACYCanada10SemaglutideAug 8, 2025
SLG DELIVERY SERVICESCanada10SemaglutideFeb 18, 2025
SUNGLOW LIFESCIENCE PRIVATE LTDIndia10SemaglutideMar 3, 2025
Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd.China10SemaglutideJul 26, 2023
Synokem Pharmaceuticals LtdIndia10TirzepatideMay 29, 2026
VS HEALTHCAREIndia10SemaglutideAug 23, 2023
Westin Resort & SpaCanada10SemaglutideMay 27, 2026
XIAMEN YUANJINCHEN TRADING CO,.LTDChina11TirzepatideMay 14, 2025
Yangzhou Aurisco Pharmaceutical Co., Ltd.China10SemaglutideJun 20, 2025
YOU DRUG MARTCanada10SemaglutideJan 21, 2026
Ziska Pharmaceuticals LimitedBangladesh10TirzepatideMay 6, 2024
Zuellig Pharma CorpPhilippines10TirzepatideJun 17, 2026

Declared manufacturers without a page

These lines count in every total and country table above. A refusal line names the declared manufacturer as entered and does not show who shipped the product.

GroupRefused linesWhy no page
Brand-name maker entered as declared manufacturer (Novo Nordisk, Eli Lilly, Bristol-Myers Squibb, Mitsubishi Tanabe, Takeda, AbbVie, AstraZeneca, Elanco, Embecta, GlaxoSmithKline)508The refusal line names the brand owner as the importer entered it; it does not show who shipped the product, so these names get no page.
Name truncated or mostly digits in FDA’s file12Names that stop at exactly 32 characters, end in a cut-off word or are mostly digits read as cut off in FDA’s file and cannot be tied to one firm, so they get no page.
Business name containing a personal name1Counted, not named.
Private individual or a name that does not read as a business80Counted, not named.

API and powder code lines, most recent first

FDA refusal chargesShipment ID
Oct 7, 2026SHANGHAI SHUNYI TRADE CO LTDChina61PIR74 TIRZEPATIDE (ANTI-DIABETIC)NonSterile PowderLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
XXX-0763321-9/1/1
Oct 7, 2026XU LIHUA JINGFANG Trading Co. LTDChina61PIR74 TIRZEPATIDE (ANTI-DIABETIC)NonSterile PowderLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users.

DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
XXX-0763336-3/1/2
Oct 7, 2026XU LIHUA JINGFANG Trading Co. LTDChina61PIR72 SEMAGLUTIDE (ANTI-DIABETIC)NonSterile PowderLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users.

DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
XXX-0763336-3/1/4
Sep 28, 2026Name not shownChina61PCR74 TIRZEPATIDE (ANTI-DIABETIC)NonSterile PowderDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.XXX-0763136-5/1/1
Sep 14, 2026BIOAMINO LABSGermany61PCZ74 TIRZEPATIDE (ANTI-DIABETIC)Sterile PowderUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).

FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
XXX-0761571-4/1/1
May 19, 2026NANJING HANXIN INTERNATIONALChina61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading.
1FX-1577805-2/10003/1
May 14, 2026Hybio Pharmaceutical (Wuhan) Co., Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.

FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
8NP-0144593-5/10002/1
Feb 25, 2026Gene ProteinsSwitzerland61PDZ74 TIRZEPATIDE (ANTI-DIABETIC)Sterile PowderUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).XXX-0735941-2/1/23
Feb 9, 2026Hybio Pharmaceutical Co., Ltd.China61PDR74 TIRZEPATIDE (ANTI-DIABETIC)NonSterile PowderFRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.799-2538313-8/10003/1
Feb 3, 2026HONG KONG KAIYS TRADING LIMITEDHong Kong61PCZ74 TIRZEPATIDE (ANTI-DIABETIC)Sterile PowderUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).

NO ENGLISH: Required label or labeling appears to not be in English in violation of 21 C.F.R. 801.15(c)(1)

FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
XXX-0732348-4/1/1
Aug 6, 2025Harbin Jixianglong Biotech Co., Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.H77-0229191-2/13/1
May 28, 2025Fujian Genohope Biotech LtdChina61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.BYA-2502829-1/12/1A
May 28, 2025Fujian Genohope Biotech LtdChina61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.BYA-2502829-1/12/1B
May 19, 2025DYNAMIC GROUPCanada61PCR74 TIRZEPATIDE (ANTI-DIABETIC)NonSterile PowderUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).

DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
SCS-0245881-3/13/1C
May 14, 2025XIAMEN YUANJINCHEN TRADING CO,.LTDChina61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).

DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.

FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
N30-0040640-4/13/1
May 1, 2025Hangzhou ThinHeal Pharma-Tech Co., Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
BYA-2501606-4/12/1
May 1, 2025Hangzhou ThinHeal Pharma-Tech Co., Ltd.China61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
BYA-2501606-4/12/2
Feb 28, 2025Fujian Genohope Biotech LtdChina61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingFRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.BYA-2500742-8/11/1
Feb 28, 2025Fujian Genohope Biotech LtdChina61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingFRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.BYA-2500742-8/11/2
Feb 28, 2025Fujian Genohope Biotech LtdChina61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingFRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.BYA-2500742-8/11/3
Oct 28, 2024Fujian Genohope Biotech LtdChina61PCS72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Further ManufNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
AEK-5719160-1/11/1
Oct 28, 2024Fujian Genohope Biotech LtdChina61PCS74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Further ManufNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).AEK-5719160-1/21/1
Aug 5, 2024Hubei JXBio Pharmaceutical Co., Ltd.China61PCZ74 TIRZEPATIDE (ANTI-DIABETIC)Sterile PowderUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).XXX-0614347-6/1/1
Apr 30, 2024JBL INTERNATIONAL HK LIMITEDHong Kong61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
799-0740432-2/11/1
Jan 25, 2024Qingdao Biopeptek Co., Ltd.China61PCR72 SEMAGLUTIDE (ANTI-DIABETIC)NonSterile PowderLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
AEK-3647198-3/11/1
Dec 6, 2023Qingdao Biopeptek Co., Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.

FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading.
AEK-3571990-3/11/1
Dec 6, 2023Qingdao Biopeptek Co., Ltd.China61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading.
AEK-3572197-4/11/1
Nov 27, 2023SHENZHEN JYMED TECHNOLOGY CO., LTD.China61PCZ74 TIRZEPATIDE (ANTI-DIABETIC)Sterile PowderUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-7891447-1/11/1
Oct 11, 2023Zhejiang Peptites Biotech Co.,Ltd.China61PDT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.906-0395480-4/11/1
Sep 27, 2023Zhejiang Peptites Biotech Co.,Ltd.China61PDT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.8V8-0000195-1/11/2
Sep 7, 2023Zhejiang Peptites Biotech Co.,Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.8GX-8000731-3/11/1
Aug 30, 2023Zhejiang Peptites Biotech Co.,Ltd.China61PCZ74 TIRZEPATIDE (ANTI-DIABETIC)Sterile PowderUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
390-9824420-3/11/1B

Other FDA import alerts searched

Each alert page below was read on Nov 15, 2026 and its text searched for semaglutide, tirzepatide, liraglutide, retatrutide and GLP-1. Alerts not in this table were not searched.

Times the page names semaglutide, tirzepatide, liraglutide, retatrutide or GLP-1
66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug SubstancesOct 9, 2026GLP-1 32, semaglutide 15, tirzepatide 14, liraglutide 1417
66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.Nov 12, 2026GLP-1 51
66-40: Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPsNov 12, 2026None0
66-66: APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122Oct 22, 2024None0
66-72: Detention Without Physical Examination Of Misbranded Drugs And Marketed New Drugs Without Approved ApplicationsOct 15, 2026None0
66-78: Detention Without Physical Examination of Drugs, Based Upon Analytic Test ResultsJul 9, 2026None0
66-79: Detention Without Physical Examination of Drugs From Foreign Establishments Refusing FDA InspectionSep 23, 2026None0
66-57: Detention Without Physical Examination of Foreign Manufactured Unapproved Prescription Drugs Distributed to Individuals in the U.S.Mar 23, 2026None0
66-76: Detention Without Physical Examination of Drugs or Active Pharmaceutical Ingredients From Facilities That Have Not Submitted Self-Identifying Information or Paid Facility or Program Fees Required Under GDUFAMar 26, 2025None0
54-16: DETENTION WITHOUT PHYSICAL EXAMINATION OF PRODUCTS THAT ARE MARKETED AS FOODS, INCLUDING PRODUCTS MARKETED AS DIETARY SUPPLEMENTS, THAT CONTAIN AN ACTIVE PHARMACEUTICAL INGREDIENTOct 15, 2026None0
55-05: Detention Without Physical Examination Of Finished Dosage Form Drug Products, Active Pharmaceutical Ingredients, and Inactive Ingredients for Potentially Hazardous Microbiological ContaminationMay 5, 2026None0
99-34: DETENTION WITHOUT PHYSICAL EXAMINATION OF DRUGS OR MEDICAL DEVICES FROM FIRMS WITHOUT A VALID DRUG OR MEDICAL DEVICE REGISTRATION AND/OR LISTINGNov 2, 2026None0

Listed firms whose entries name a GLP-1 term

Alert and listFirmCountryProducts as FDA lists them
66-41, Red List
added Jun 23, 2026
Hebei Houde Hanfang Medical Devices Co., Ltd.
Jinhe Int'L Business Bldg. A Room 1603, Huaan West Street, Shijiazhuang, Hebei CHINA
CHINA66V--99 Miscellaneous Patent Medicines, Etc.: GLP-1 Transdermal Patches
66V--99 Miscellaneous Patent Medicines, Etc.: Adhesive Patch

66Y--99 Exhibits - Other Drug Related Items N.E.C.: GLP-1 Transdermal Patches

66Y--99 Exhibits - Other Drug Related Items N.E.C.: Adhesive Patch

79K--GX Tape And Bandage, Adhesive: GLP-1 Transdermal Patches

79K--GX Tape And Bandage, Adhesive: Adhesive Patch

80K--ME Bedding, Disposable, Medical: GLP-1 Transdermal Patches

80K--ME Bedding, Disposable, Medical: Adhesive Patch

80Q--IX System, transdermal Ddlivery, CDER or CBER led: GLP-1 Transdermal Patches

80Q--IX System, transdermal Ddlivery, CDER or CBER led: Adhesive Patch

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.